Associates in Poland
and abroad
Global
English
Global
English
Global
English
Poland
polski
Czechia
Český
Italy
Italiano
Kazakhstan
Қазақ
Slovakia
Slovenský
Spain
Español
Ukraine
Українськa
Uzbekistan
Ўзбекча
Vietnam
Tiếng việt
x
About Adamed
This is where Polish innovation is born
We are a family-owned pharmaceutical and biotechnology company with 100% Polish capital, built on the foundation of Polish scientific thought and our own patents.
Since the establishment of Adamed in 1986, we have grown into one of the most prominent pharmaceutical companies in Poland, exporting Polish innovation to global markets. We rank among the top ten largest pharmaceutical companies operating in the country (source: IQVIA).
Adamed is a leader in the next-generation medicine market – in 2001, we were the first company in Poland to launch research and development work on original therapies. Today, our portfolio includes nearly 900 products (SKUs) in Poland and abroad, offered to patients in dozens of countries worldwide. To date, we have allocated nearly 2.6 billion PLN for research and development investments. We cooperate with leading universities and scientific institutes, both domestically and internationally.
40 years of innovation, over 130 years of tradition
1986
Adamed was founded by Marian Adamkiewicz MD, PhD
1991
- The first drug for treatingurinary tract infections is launched.- The development of an original technology for producing high-grade furaginum makes treatment for urologic conditions available to millions of patients
1994
The first manufacturing facility is opened in Pieńków, near Warsaw1998
- The first Polish-made amlodipine is registered.- The method of synthesising amlodipine is improved: the new production process, that was first developed in Poland, means the number of patients who can benefit from the therapy has grown significantly, from 75,000 to more than 1.5 million today
1999-2001
- The Research and Development Division is established.- Adamed meets the standards of good manufacturing practice established by the European Union and is awarded the GMP EU certificate
- Research into innovative drugs (in the areas of oncology and central nervous system diseases) is initiated
2002
A second manufacturing plant is opened in Ksawerów, near Łódź2003
Adamed starts exporting its products2005-2009
- The first industry-academia consortium is formed with the Jagiellonian University- Start of operations of Adamed Laboratorios in Spain
- Establishment of a representative office in Ukraine
2010
Acquisition of Polfa Pabianice and Agropharm
2011
Change of availability category for the drug FURAGUINUM from RX to OTC
2013
Establishment of a branch in Kazakhstan2016
Adamed’s state-of-the-art R&D Centre becomes operational
2016
The company establishes branches in Slovakia and the Czech Republic
2017
Acquisition of a controlling interest in the Vietnamese pharmaceutical company Dat Vi Phu
2018
Pilot R&D Production Area (Pilot Plant) becomes operational
2019
Establishment of a branch in Italy and acquisition of a block of shares in the Italian company Ecupharma
2020
- An exclusive global license agreement is signed with Acadia Pharmaceuticals for further development of Adamed’s innovative molecule- Establishment of a representative office in Uzbekistan
2021
Expansion of the Production and Logistics Center in Pabianice
2022
The world's first change in the category of Tadalafil 10 mg availability from RX to OTC
2023
Acquisition of 100 percent shares of the Vietnamese company Davipharm
2024
Opening of new laboratories for inhalation drug development and microbiology
2025
ADAMED Discovery research centre opens in Kajetany near Warsaw